144 related articles for article (PubMed ID: 36908321)
1. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models.
Liu XM; Xia SY; Long W; Li HJ; Yang GQ; Sun W; Li SY; Du XH
World J Gastrointest Oncol; 2023 Feb; 15(2):332-342. PubMed ID: 36908321
[TBL] [Abstract][Full Text] [Related]
2. Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer.
Wen D; Wang Y; Zhu Z; Huang Z; Cui L; Wu T; Liu CY
Biochim Biophys Acta Mol Basis Dis; 2020 Dec; 1866(12):165923. PubMed ID: 32800944
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
Hashimoto M; Masuda T; Nakano Y; Tobo T; Saito H; Koike K; Takahashi J; Abe T; Ando Y; Ozato Y; Hosoda K; Higuchi S; Hisamatsu Y; Toshima T; Yonemura Y; Hata T; Uemura M; Eguchi H; Doki Y; Mori M; Mimori K
Cancer Sci; 2024 Jun; 115(6):1866-1880. PubMed ID: 38494600
[TBL] [Abstract][Full Text] [Related]
5. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
[TBL] [Abstract][Full Text] [Related]
6. Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway.
Wei LH; Lin JM; Chu JF; Chen HW; Li QY; Peng J
Chin J Integr Med; 2017 Nov; 23(11):858-863. PubMed ID: 29080197
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death.
Kuang C; Tong J; Ermine K; Cai M; Dai F; Hao S; Giles F; Huang Y; Yu J; Zhang L
Front Oncol; 2022; 12():1018775. PubMed ID: 36313707
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
[TBL] [Abstract][Full Text] [Related]
11. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.
Fourniols T; Maggio V; Rafael D; Colaco A; Vidal EG; Lopes A; Schwartz S; Martínez-Barriocanal Á; Preat V; Arango D
Eur J Pharm Biopharm; 2022 Feb; 171():39-49. PubMed ID: 34998911
[TBL] [Abstract][Full Text] [Related]
13. BET inhibition induces synthetic lethality in PTEN deficient colorectal cancers via dual action on p21
Ren G; Chen J; Pu Y; Yang EJ; Tao S; Mou PK; Chen LJ; Zhu W; Chan KL; Luo G; Deng C; Shim JS
Int J Biol Sci; 2024; 20(6):1978-1991. PubMed ID: 38617536
[TBL] [Abstract][Full Text] [Related]
14. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
15. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
17. Physciosporin suppresses the proliferation, motility and tumourigenesis of colorectal cancer cells.
Taş İ; Han J; Park SY; Yang Y; Zhou R; Gamage CDB; Van Nguyen T; Lee JY; Choi YJ; Yu YH; Moon KS; Kim KK; Ha HH; Kim SK; Hur JS; Kim H
Phytomedicine; 2019 Mar; 56():10-20. PubMed ID: 30668330
[TBL] [Abstract][Full Text] [Related]
18. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
Damaneh MS; Hu JP; Huan XJ; Song SS; Tian CQ; Chen DQ; Meng T; Chen YL; Shen JK; Xiong B; Miao ZH; Wang YQ
Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
[TBL] [Abstract][Full Text] [Related]
19. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
